Citius Pharmaceuticals IncCTXR
Price$0.54

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.6MTTM through 30 Jun 2026
Net Income -$58.2MTTM through 30 Jun 2026
Free Cash Flow -$34.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin80.0%
Operating Margin-1,931.0%
Net Margin-1,686.0%

Returns

-45.7%ROE
-21.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.58x
Net Debt-$4.6Mnet cash position
Cash & Equivalents$17M

Quality Metrics

Altman Z-Score-4.03
Piotroski F-Score2 / 9
FCF Margin-621.4%
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'17'18'19'20'21'22
FY2022: $90K
Diluted EPS-$1.75TTM
'11'12'13'21'22'23
FY2023: $-5.38

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.